The fate of P2Y-related orphan receptors: GPR80/99 and GPR91 are receptors of dicarboxylic acids by Gonzalez, Nathalie Suarez et al.
Review




1,S e ´bastien Hannedouche
3 & Jean-Marie Boeynaems
1,2
1Institute of Interdisciplinary Research, School of Medicine, Free University of Brussels, Brussels, Belgium;
2Laboratory
of Medical Chemistry, Erasme Hospital, Free University of Brussels, Brussels, Belgium;
3Euroscreen Inc., Brussels,
Belgium
Received 30 August 2004; accepted in revised form 15 October 2004
Key words: a-ketoglutarate, G-protein coupled, nucleotide, orphan, P2Y, receptor, succinate
Abstract
Several orphan G protein-coupled receptors are structurally close to the family of P2Y nucleotide receptors: GPR80/99
and GPR91 are close to P2Y1/2/4/6/11 receptors, whereas GPR87, H963 and GPR34 are close to P2Y12/13/14. Over the
years, several laboratories have attempted without success to identify the ligands of those receptors. In early 2004, two
papers have been published: One claiming that GPR80/99 is an AMP receptor, called P2Y15, and the other one showing
that GPR80/99 is a receptor for a-ketoglutarate, while GPR91 is a succinate receptor. The accompanying paper by Qi
et al. entirely supports that GPR80/99 is an a-ketoglutarate receptor and not an AMP receptor. The closeness of
dicarboxylic acid and P2Y nucleotide receptors might be linked to the negative charges of both types of ligands and the
involvement of conserved Arg residues in their neutralization.
Introduction
One of the most comprehensive and recent analysis of the
human genome concluded that the repertoire of G protein-
coupled receptors for endogenous ligands consists of 367
human genes and 392 murine genes [1]. At that time, 187
among the 367 human receptors remained orphan, but the
ligands of a few of them have now been identified. Of
those 187 orphan receptors, 51 were considered to belong
to families with known ligands, on the basis of phyloge-
netic analysis. The P2Y family of nucleotide receptors is
subdivided into two structurally distant subfamilies [2]. A
first group includes the P2Y1, P2Y2,P 2 Y 4,P 2 Y 6 and
P2Y11 receptors. P2Y12, P2Y13 and P2Y14 belong to a
second group. Vassilatis et al. included three orphan
receptors in the P2Y family: GPR80 (also called GPR99)
and GPR91 in the first group, and GPR87 in the second
one. Other orphan receptors (H963 and GPR34) are also
close to the last group (Figure 1). A previous phylogenetic
analysis had reached the same conclusions [3]. The
inclusion of GPR80/99 and GRP91 in the P2Y family
was further supported by the presence in their sequence of
structural motifs conserved among genuine P2Y receptors
[2]. Indeed, all P2Y receptors belonging to the first group
(P2Y1/2/4/6/11) have one histidine and one arginine/lysine
residues in transmembrane domain (TM) 6 and one
arginine residue in TM7 (Figure 2). In the case of the
P2Y2 receptor, mutagenesis experiments have demonstrat-
ed that these residues play a crucial role in receptor
activation by ATP/UTP [17].
History of GPR91 and GPR80/99
The first description of human GPR91 dates back to 1995
[4]. At the time, it was called P2U2 because it was closest
to the then P2U – now P2Y2 – receptor (31% amino acid
identity). Northern blot revealed an abundant expression of
mRNA in the kidney, but expression was also detected in
megakaryocytic cell lines, mainly DAMI cells. It was
reported in a patent application that Xenopus oocytes
expressing P2U2 mRNA became responsive to nucleotides
with the following rank order of potency: UTP9UDP9
ADP9ATP [5]. The same human receptor and its murine
ortholog were rediscovered using an expressed sequence
tag data mining strategy and called GPR91 [6]. Again, a
high expression of the human mRNA was found in the
kidney, while the murine one was also present in the liver.
The human GPR91 gene was located on the chromosome
3q24–3q25, where it belongs to a cluster including also the
P2Y1, P2Y12, P2Y13 and P2Y14 genes [2, 6].
In 2000, Communi et al. discovered a new P2Y-like
sequence by RT-PCR homology cloning based on the
sequences of P2Y1 and P2Y11 receptors (Communi et al.,
unpublished data). That receptor was stably expressed in
1321N1 and CHO-K1 cells. Although initial data obtained
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new receptor could be an ADP receptor, the ADP response
was not confirmed by inositol phosphates or cAMP
measurements and was apparently due to the degradation
of ADP into adenosine (Communi et al., unpublished data).
Northern blots were negative for several human organs but
gave a strong positive signal for the human thyroid gland
(Communi et al., unpublished data). Using genomic
sequences database search and PCR, Lee et al. reported
the existence of the same sequence under the name GPR80
and noticed its relatedness to P2Y receptors [7]. Northern
blots were negative for various brain regions. The same
sequence was also described later by Wittenberger et al.
[8], who called it GPR99 and mapped the gene on
chromosome 13q32.2. Following expression in oocytes,
these authors failed to detect any response to a range of
nucleotides. Northern blotting revealed a signal in kidney
and a weaker one in placenta.
Identification of GPR81 and GPR80/GPR99 ligands
In March 2004, Inbe et al. [9] reported that in HEK293 cell
clones stably expressing HA-tagged GPR80/99, AMP
induced Ca
2+ mobilization and cAMP generation, while it
had almost no effect on untransfected cells. These responses
were inhibited by theophylline and other xanthines. Fur-
thermore they detected a binding of [
32P]AMP to HEK293
cells expressing GPR80/99. Quantitative RT-PCR revealed
expression in the kidney, as mentioned earlier, but also in
the trachea and mast cells. The authors speculated that
GPR80/99, that they renamed P2Y15, could be the target
responsible for the bronchodilatory action of theophylline.
Another paper identifying the ligands of GPR80/99 and
GPR91 appeared in May 2004 [10]. To deorphanize
GPR91, these authors started from the observation that its
mRNA is strikingly abundant in one organ: The kidney.
Following RP-HPLC purification of a kidney extract, one
fraction was able to activate GPR91 expressed in CHO
cells and was found to contain succinate. In HEK293 cells
stably expressing GPR91, succinate (10–100 mM) in-
creased inositol phosphate formation (with partial inhi-
bition by pertussis toxin) and inhibited the formation of
cAMP, thus indicating dual coupling to Gq/11 and Gi.B y
analogy GPR80/99 was found to be responsive to another
Figure 1. Phylogenetic tree illustrating the relatedness of the two groups
of P2Y receptors, dicarboxylic acid receptors, receptors for short-chain
monocarboxylic acids and remaining orphan P2Y-like receptors. The
following receptors are included in the tree: P2Y receptors, group I: P2Y1,
P2Y2, P2Y4, P2Y6 and P2Y11; P2Y receptors, group II: P2Y12, P2Y13 and
P2Y14; Dicarboxylic acid receptors: succinate (GPR91) and a-ketogluta-
rate (GPR80/99); Monocarboxylic acid (propionate) receptors: GPR41 and
GPR43; Orphan P2Y-like receptors: GPR87, H963 and GPR34. Align-
ment was performed using ClustalX algorithm and the dendrogram was
constructed using the TreeView algorithm.
Figure 2. Role of conserved positively charged residues in the activation of P2Y and dicarboxylic acid receptors by their respective ligands. Conserved
residues among P2Y and/or dicarboxylic acids receptors are shown in a higher size font. The residues that have been mutated in the studies of Erb et al.
[17], Jiang et al. [14] and He et al. [10] are underlined. Those residues that are crucial in the activation of those receptors are in bold.
18 N.S. Gonzalez et al.citric acid cycle intermediate: a-ketoglutarate. In contrast
with GPR91, it coupled exclusively to Gq/11. Almost 30
years ago, extracellular succinate was shown to induce
renin release from the kidney in vitro: He et al. [10] showed
that i.v. succinate stimulated the release of renin in mice
and that this effect is abolished in GPR91-deficient mice.
The demonstration that GPR91 is a succinate receptor
and GPR80/GPR99 a receptor for a-ketoglutarate is very
strong [10]. In contrast, the report that GPR80/GPR99
would be the P2Y15 receptor of AMP suffers from one
major pitfall: The pharmacological properties of GPR80/
GPR99 were evaluated in a single expression system, the
HEK293 cells [9]. It is indeed known that HEK293 cells
expressed endogenous A2B receptors coupled to both Gq and
Gs [11]. As expected, Inbe et al. [9] found an endogenous
response to adenosine, though not AMP, in untransfected
HEK293 cells. There was apparently no difference in AMP
degradation into adenosine between the plain HEK293 cells
and the clone expressing GPR80/GPR99. However, the
level of A2B receptor expression might vary between
different clones of HEK293 cells. This explanation is
consistent with the results presented in the accompanying
paper by Qi et al. [18] who failed to detect any response to
adenosine or AMP in either COS-7, CHO-K1 or HEK293
cells expressing HA-tagged GPR80/99, whereas in the same
cells these authors found a striking response to a-ketoglu-
tarate. We made similar observations in a CHO-K1 cell line
co-expressing Ga16 and apoaequorin (Figure 3).
Discussion
For several years it was believed that GPR80/99 and
GPR91 were potential P2Y receptors. This belief was
supported by sequence homology, conservation of charac-
teristic positively charged residues in TM6 and TM7, and
even chromosomal location in case of GPR91. However
He et al. [10] have now provided a clear-cut demonstration
that GPR91 is a succinate receptor and GPR80/99 a
receptor for a-ketoglutarate. The recent report by Inbe
et al. [9] that GPR80/99 would be a receptor for AMP,
called P2Y15, represents a source of confusion. The
accompanying paper by Qi et al. [18], as well data from
other groups (Communi et al., unpublished data; [8]),
demonstrate that GPR80/99 is not an AMP receptor and
should not be associated with the name P2Y15. One might
wonder if the structural closeness of dicarboxylic acid and
P2Y nucleotide receptors is merely fortuitous. Succinate is
very close chemically to propionate and butyrate, which
have their own receptors [12, 13]: GPR41 and GPR43.
Interestingly, the succinate and a-ketoglutarate receptors
are closer to the first group of P2Y receptors than to these
receptors for short-chain monocarboxylic acids (Figure 1).
Furthermore, three of the positively charged residues
characteristic of the P2Y family and the importance of
which has been established by mutagenesis [14, 17], an
Arg residue in TM3 (Arg99), an Arg residue in TM6
(Arg252) and another Arg residue in TM7 (Arg281),
appear to be involved in the binding of the dicarboxylic
acids, since their mutation in GPR91 abolished the
responsiveness to succinate [10]. This suggests that some
of the residues involved in neutralizing the phosphate
negative charges of nucleotides play the same role towards
the carboxylate negative charges of dicarboxylic acids
(Figure 2). In conclusion, GPR80/99 and GPR91 are
dicarboxylic acid receptors and not P2Y receptors, and
the name P2Y15 should not be used to designate GPR80/99,
which is a receptor for a-ketoglutarate.
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